Organogenesis (ORGO) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SIGA Technologies (SIGA) has outperformed Organogenesis (ORGO) over the past year, losing 61.4% versus a loss of 68.1%. Over five years, SIGA leads with a -54.1% price change compared with -87.9% for ORGO. SIGA Technologies is the larger company by market cap ($235.7 million vs $164.7 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORGO | SIGA |
|---|---|---|
| Share price | $1.28 | $3.28 |
| Market cap | $164.70M | $235.67M |
| 1-day change | -3.03% | +0.61% |
| YTD return | -74.52% | -46.64% |
| 1-year return | -68.12% | -61.37% |
| 5-year return | -87.95% | -54.15% |
| Forward P/E | — | 3.04 |
| EPS (TTM) | $-0.83 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.08 | $8.55 |
| 52-week low | $1.25 | $2.83 |
| Distance from 52-week high | -81.91% | -61.64% |
| Analyst consensus | none | none |
| Avg. price target upside | +56.25% | — |
| Average volume | 772.95K | 726.50K |
| Shares outstanding | 128.67M | 71.85M |
| Employees | 854 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
ORGO vs SIGA FAQ
Which is bigger, Organogenesis or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $235.67M compared with $164.70M for Organogenesis (ORGO).
Which stock has performed better over the past year, ORGO or SIGA?
SIGA returned -61.37% over the past 12 months, compared with -68.12% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are Organogenesis and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.